GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Current Accrued Expense

Savara (STU:YB4P) Current Accrued Expense : €5.50 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Savara Current Accrued Expense?

Savara's Current Accrued Expense for the quarter that ended in Jun. 2024 was €5.50 Mil.

Savara's quarterly Current Accrued Expense increased from Dec. 2023 (€2.66 Mil) to Mar. 2024 (€5.57 Mil) but then declined from Mar. 2024 (€5.57 Mil) to Jun. 2024 (€5.50 Mil).

Savara's annual Current Accrued Expense increased from Dec. 2021 (€1.97 Mil) to Dec. 2022 (€1.99 Mil) and increased from Dec. 2022 (€1.99 Mil) to Dec. 2023 (€2.66 Mil).


Savara Current Accrued Expense Historical Data

The historical data trend for Savara's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Current Accrued Expense Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.36 2.86 1.97 1.99 2.66

Savara Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 3.21 2.66 5.57 5.50

Savara Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Savara Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Savara's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara Business Description

Traded in Other Exchanges
Address
1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara Headlines

No Headlines